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Abstract
Short tandem repeat (STR) analysis, such as the AmpFlSTRH IdentifilerH Plus kit, is a standard, PCR-based human genotyping
method used in the field of forensics. Misidentification of cell line and tissue DNA can be costly if not detected early;
therefore it is necessary to have quality control measures such as STR profiling in place. A major issue in large-scale research
studies involving archival formalin-fixed paraffin embedded (FFPE) tissues is that varying levels of DNA degradation can
result in failure to correctly identify samples using STR genotyping. PCR amplification of STRs of several hundred base pairs
is not always possible when DNA is degraded. The Sample ID PlusH panel from Sequenom allows for human DNA
identification and authentication using SNP genotyping. In comparison to lengthy STR amplicons, this multiplexing PCR
assay requires amplification of only 76–139 base pairs, and utilizes 47 SNPs to discriminate between individual samples. In
this study, we evaluated both STR and SNP genotyping methods of sample identification, with a focus on paired FFPE
tumor/normal DNA samples intended for next-generation sequencing (NGS). The ability to successfully validate the identity
of FFPE samples can enable cost savings by reducing rework.
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Introduction
STR profiling is a powerful, multiplex PCR-based assay that
uses up to 16 tetranucleotide loci repeats [1,2]. Generally, the
certainty of identity with one locus is less than 0.01, and is
1.0610215 for 12 or more loci, making STR a very effective
method for sample identification [2,3]. Despite its efficacy,
improvements to STR assays have been required for forensic
analysis on highly-degraded DNA samples, namely reducing
amplicon size to increase amplification efficiency [4,5]. Previous
studies on degraded DNA have demonstrated that STR analysis
using amplicons of 280 nt or less generates 48% more genotype
profiles than would be possible with longer STRs [5]. STR
analysis has been advocated by the American Type Culture
Collection Standards Development Organization (ATCC SDO)
Workgroup for human cell line authentication in general [6,7].
Monitoring sample quality at the beginning of a process is
especially essential to ensure that cell lines and tissues are
authenticated for correct input DNA in order to ensure validity
of data output [8]. Failure to authenticate samples may result in
unwanted, incorrect, or duplicate data; consequently, these
superfluous errors can be costly. Common causes leading to
sample misidentification include mislabeling of cell cultures or
DNA samples, cross-contamination, co-cultivation, and xenograft
propagation. For example, it has been revealed that at least
360 cell lines are known to have some cross-contamination [9].
Furthermore, STR profiling demonstrated the misidentification of
multiple ovarian cancer cell lines [10]. Formalin fixed paraffin
embedded (FFPE) sample misidentification is likely to occur from
some of the same types of errors and circumstances. Next
generation sequencing (NGS) technology has rapidly progressed
and expanded over the past decade [11,12]. With such abrupt
growth and development, there is an increasing need for accuracy
at each stage of a sequencing pipeline. Quality control checkpoints
are typically implemented throughout the process, including STR
profiling which is now regularly used to verify sample identity after
sample reception, or before NGS library preparation. Further-
more, with NGS technology now capable of producing whole
genome and exome data from FFPE-derived DNA, it will be
beneficial for 100% of tissue authentication to be successful despite
inputs of fragmented DNA. In a clinical setting, FFPE tissues are
an indispensable DNA resource and the standard for pathological
examination of tissues; however, this preservation method is
typically prone to analyte degradation [13]. To accommodate
such DNA size limitations for NGS sample quality control, a
further reduction in amplicon size is necessary. A single nucleotide
polymorphism (SNP) genotyping panel has been designed to
require amplification of shorter targets, and provide greater than
1610218 discriminatory power [14,15]. This study explores the
use of Sample ID PlusH SNP assay technology (Sequenom
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Bioscience, San Diego, CA) in generating complete genotype
profiles from FFPE tissue DNA.
Materials and Methods
Ethics Statement
FFPE samples were taken as part of a larger NGS study of
genomic prognostic factors within pre-treatment biopsies derived
from prostate cancer patients with Institutional Review Board
(IRB) approval and patient written consent (Canadian Prostate
Cancer Genome Network (CPC-GENE) project; University
Health Network-Research Ethics Board UHN06-0822-CE and
UHN11-0024CE [16]. The samples analyzed in this study were
taken from a larger deep-sequencing dataset deposited in the
European Genome-phenome Archive (dataset ID
EGAS00001000549).
Sample Extraction
DNA was extracted from patient blood samples (N1-2, N2-2,
N3-2, AND N4-2) using the ArchivePure DNA Blood Kit from 5
Prime (Gaithersburg, MD) following the manufacturer’s recom-
mended protocol. DNA was also extracted from corresponding
FFPE prostate tumors (T1-2, T2-2, T3S1-2/T3S2-2, and T4-2).
Two different sections of tumor sample 3, T3S1-2 and T3S2-2,
were extracted and tested as individual samples, but were both
paired with N3-2. The approximate age of the FFPE tissue blocks
were as follows: T1-2, 5 years; T2-2 and T4-2, 8 years; T3S1-2
and T3S2-2, 11 years. FFPE prostate tumors were macro-
dissected, proteinase K-treated, and phenol-chloroform extracted
using a modified protocol based on the xylene-free MagMAX
FFPE DNA Isolation Kit (Life Technologies, Carlsbad, CA).
STR Genotyping
For STR profiling with the AmpFlSTRH IdentifilerH Plus PCR
Amplification Kit (Applied Biosystems, Foster City, CA), 25 ng of
FFPE tumor/normal DNA or 5 ng of R1 reference DNA was
used. Data were analyzed using GeneMarker HID V1.95. The
mean size of the 15 STR markers evaluated in this study range
from 101–359 nt; the amelogenin sex determination marker was
excluded from analysis for simplicity since gender information was
not required. STR marker sizes are displayed as calculated
fractions based on comparisons to internal size standards
performed by Applied Biosystems. Individual markers have
variable, but specific size ranges.
Multiplex PCR FFPE DNA Quality Assessment
For multiplexed PCR, four primer pairs (IDT) were used to
amplify 100, 200, 300, and 400 bp non-overlapping regions of the
GAPDH gene from 5 ng of each sample [17]. The products were
amplified in a 50 ml reaction, the final concentrations of 100 F/R
and 300 F/R were 0.133 mM, 200 F/R were 0.200 mM, and
400 F/R were 0.067 mM. Multiplex PCR reaction conditions
were as follows: 98uC for 30 sec, followed by 35 cycles each of
98uC for 10 sec, 62uC for 30 sec, and 72uC for 30 sec with a final
10 min extension at 72uC. PCR was carried out using 1 U
Phusion HF Taq DNA polymerase and buffer (NEB, Ipswitch,
MA), 500 mM KCl, and 10 mM dNTPs (Invitrogen, Carlsbad,
CA). For positive controls, the same PCR reaction was performed
on corresponding normal samples, as well as on a reference
prostate gDNA, R1. A no template control (NTC) consisting of
nuclease-free water (Ambion, Carlsbad, CA) was also included. All
PCR reactions were purified using the MinElute PCR Cleanup
Kit (QIAGEN, Venlo, Netherlands), and quantified with a Qubit
1.0 fluorimeter (Invitrogen). To evaluate GAPDH amplification,
gel electrophoresis was performed on PCR reactions using a 2%
agarose gel. PCR product sizes and quantity of approximately 100,
200, 300, 400 bp were confirmed with a DNA Bioanalyzer assay
(Agilent Technologies, Santa Clara, CA).
SNP Genotyping
For Sequenom Bioscience’s Sample ID PlusH panel, 10 ng of
FFPE tumor/normal DNA or 2.5 ng of R1 reference DNA was
used to determine 47 SNP calls; however a total of 45 SNPs were
evaluated due to the general failure of two SNP calls, rs735155
and rs1029047. These two SNP calls also failed consistently in
previous, unrelated assay tests; therefore, they were excluded from
our analysis. In addition, other studies have observed similar poor
performances for rs735155 and rs1029047 [18]. This method
consists of five steps: PCR amplification, shrimp alkaline
phosphatase treatment, single base extension, nanodispensing,
and matrix-assisted laser desorption/ionization time of flight
(MALDI-TOF) mass spectrometry [19]. Two previously con-
firmed primary non-FFPE tumor/normal pair matches (Pos1-T,
Pos1-N and Pos2-T, and Pos2-N) were used as positive controls.
Two mouse samples, Neg1 and Neg2, were used as negative
controls. NTC wells were also included on the assay plate. All SNP
calling from Sequenom Typer v4.0.20 software reports was
analyzed using Microsoft Excel 2010 spreadsheets. Sex determi-
nation markers were noted but excluded from analysis to retain
consistency with STR profiling analysis. Current SNP amplicon
sizes ranged from 76–139 bp. Heat map analysis plots were
generated by R v2.15.1.
DNA Fragmentation
To simulate limited DNA size as observed in FFPE samples,
3 mg of reference gDNA, R1, was fragmented by sonication using
a Covaris S2 instrument. Performance of a shearing time-course
determined that 75 sec was an appropriate shearing time for this
sample in order to obtain a broad fragment range when standard
400 bp DNA shear conditions were applied as follows: 10% duty
cycle, intensity 4, 200 cycles per burst, 6–8uC water bath. The R1
shearing profile was confirmed with a DNA Bioanalyzer assay,
followed by electrophoresis with a 2% agarose gel. From this gel,
size selection was done manually for targeted R1 fragment pools of
approximately 100, 200, 300, and 400 bp. These sizes were
selected to coincide with GAPDH target regions used for prior
FFPE DNA quality assessment. Gel cuts were purified with
Zymoclean Gel DNA Recovery columns (Zymo Research, Irvine,
CA). Purified R1 pools were quantified with a Qubit 1.0
fluorimeter (Invitrogen). Using a DNA Bioanalyzer assay, actual
size-selected R1 targets were detected as 132, 233, 347, and
450 bp, and fragment pools were correspondingly named R1 132,
R1 233, R1 347, and R1 450.
Results and Discussion
To confirm FFPE sample identification, STR profiling was
performed. Typically, at least 80% or more of alleles are required
to match in order to properly authenticate DNA samples using
STR profiling [20]. However, recent examinations indicate that,
depending on the sample type, even more stringent thresholds
would be beneficial for validating sample identity [21]. For
sensitive and costly downstream applications such as NGS, at least
85% concordance was more reliable. Profiles were successfully
obtained for all normal samples; however, several STRs consis-
tently failed for each tumor sample (Figure 1). The failed STR
markers ranged from 255–359 nt. Except for the success of the
274 nt D16S539 marker, data suggest that failure to generate a
Sequenom SNP Genotyping of FFPE Tumor Samples
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complete profile for FFPE samples was likely due to fragmentation
and degradation of DNA impeding amplification of the larger
amplicons. To predict successful array comparative genomic
hybridization (aCGH) with FFPE DNA, van Beers et al.
established a reliable multiplexed PCR assay which targeted
100, 200, 300, and 400 bp non-overlapping regions of the
GAPDH gene [17]. We applied this assay to our FFPE tumor/
normal pairs to explore the effects of DNA fragment size on
successful amplification. Although all GAPDH regions amplified
for all normal samples, PCR products were not seen for all four of
the targeted regions for the corresponding tumor samples (Figure
S1). The inability to amplify the larger GAPDH targets in FFPE
samples implied that fragmentation of DNA could affect detection
of loci greater than 200 bp in length. However, this result is not
exhaustive, as formalin fixation can alter the DNA is other ways
which could contribute to whether or not detection is possible
[22,23].
To evaluate the capability of SNP genotyping to confirm the
identities of the FFPE tumor/normal pairs subjected to STR
profiling, samples were processed with Sequenom Bioscience’s
Sample ID PlusH panel. The average number of matched SNP
calls between unrelated samples in previously-developed identifi-
cation panels has been described as 40.38%, and ranging from
13.46–78.85% [14]. Additionally, Gilbert et al. observed a 86–
100% matched call rate on relatively higher quality FFPE samples
when utilizing a similar 44-SNP genotyping method [24].
According to Sequenom Bioscience, samples are called mismatch-
es when less than 30 SNP calls are concordant. However, to be
consistent with the concordance rate of 85% we used for STR
profiling, at least 38 SNP matches were required in our study.
Heat map analysis illustrated that all FFPE tumor/normal pairs
were detected (Figure 2). The T1-2/N1-2 pair displayed a 97.78%
(44/45) call rate, as the rs104954 locus did not match. All other
tumor/normal pairs and positive control pairs obtained 100% call
rates. In addition, all other possible sample-sample, control-
control, and sample-control combinations showed 0–51.11% (0–
23) matched SNP calls, indicating no other relationships existed.
Overall, successful SNP genotyping profiles were obtainable for
FFPE tumor DNA, despite incomplete STR profiles. Furthermore,
STR loci are more likely to have greater genetic instability than
biallelic SNPs [25]. This and other factors, such as relatedness,
could affect the minimal match threshold of an FFPE tumor/
normal pair. However, the high success rate of SNP genotyping in
this case renders these factors insignificant when compared to
STR profiling results. These data demonstrated the efficacy and
sensitivity of the Sequenom Bioscience’s Sample ID PlusH SNP
genotyping panel over typical STR profiling methods, especially in
the case of FFPE or types of highly-degraded samples.
To further support that SNP genotyping, compared to STR
profiling, is largely unaffected by target DNA size we devised a
three-step approach: shear a reference DNA sample and separate
into fragment pools, submit pools to STR profiling, and perform a
SNP genotyping assay on the same pools. STR genotyping was
performed on each sheared R1 fragment pool, and on intact R1
gDNA using the same methods described for the FFPE tumor/
normal pairs (Table 1). All STR markers amplified successfully for
R1 450, R1, C1, and C2. Six STR markers ranging from 216–
359 nt expectedly failed for R1 132. Additionally, the larger
TH01, vWA, D21S11, TPOX, and FGA STR markers were
profiled successfully for R1 132. Bioanalyzer traces revealed that
trace amounts of larger DNA fragments were present in the R1
132 fragment pool, which is likely why these unexpected STR
markers amplified. All other STR marker failures were consistent
with the R1 fragment pool size cutoffs, with the exception of
CSF1PO, which failed for R1 347 despite its average size of
324 nt.. It was important to determine if SNP genotyping could be
more effective at generating complete identification profiles than
STR profiling using samples of known fragment size. For each
Figure 1. Frequency of STR marker detection. T1-2/N1-2, T2-2/N2-2, T3S1-2/T3S2-2/N3-2, T4-2/N4-2 tumor and normal samples are represented
by bars only when an STR marker was successfully amplified. Nucleotide size ranges are listed above the corresponding STR marker.
doi:10.1371/journal.pone.0088163.g001
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sample, Figure 3 displays all SNP amplicons in the assay based on
size, and classifies each as failed or successful. One SNP (dbSNP
ID rs733164) failed to amplify for R1 and all fragment pools,
despite its amplicon length of 128 bp. All other 44 SNP amplicons
were successfully called for R1, R1 233, R1 347, and R1 450,
providing a 97.78% call rate. In contrast, only 66.67% (30/45) of
SNP calls were detected for R1 132. To reach the STR profiling
concordance rate of 85%, at least 38 SNP calls are required to
match. For all 15 failed SNP calls for R1 132, the amplicon sizes
ranged from 97–139 bp, while the sizes varied from 76–138 bp for
the successful SNP amplicons. Therefore, there appeared to be no
direct relationship between amplicon size and a SNP’s successful
detection. However, 97.78% (44/45) of SNP calls were detected
when approximately twice the amount (5 ng) of R1 132 DNA
input was utilized for genotyping, suggesting that the assay may be
more sensitive to sample input quantity when DNA is fragmented
due to the lower amounts of intact amplicon target. Johansen et al.
described the impact of low DNA input amounts on allelic
dropouts as well [18]. Overall, these fragment pool results support
that DNA fragment integrity can limit STR profiling success,
whereas DNA sample quantity, but not amplicon size, affects SNP
genotyping results.
SNP genotyping analysis was successful for FFPE tumors and
the R1 132 and R1 233 fragment pools, where STR profiling
efforts were rendered incomplete. Table 2 summarizes the input
and results comparison between each genotyping method.
Extraction method and sample age are variables that may have
contributed to poor FFPE DNA quality, and subsequent STR
failure. A method recently developed to extract DNA from FFPE
tissue by xylene-free deparaffinization was directly compared to
the QIAamp DNA FFPE Tissue Kit (QIAGEN), and showed that
although greater yields were recovered, the DNA integrity suffered
[26]. Another study showed that application of an automated,
xylene-free deparaffinization approach allowed for 99% of samples
to be analyzed by SNP genotyping, which yielded higher than
91% SNP calls [27]. In our study, FFPE tissues were not
deparaffinized using xylene; instead the proteinase K incubation
time was extended to last overnight at 55uC to maximize DNA
recovery. The age of FFPE tissue blocks has also been shown to
negatively affect DNA quality and quantity, especially after 5–6
years of storage [28]. For our study, all FFPE tumor DNA was
extracted from blocks ranging in age from 5–11 years. Age alone is
likely not the single factor here but rather changes in formalin
fixation protocols in the intervening years. Comparative DNA
extraction method studies employing STR analysis on FFPE
tissues of variable age have indicated that increased storage time,
extraction method, and reagent quality all play key roles in poor
DNA quality [23]. Additionally, the aforementioned study
Figure 2. FFPE tumor/normal pair relatedness assessed by Sequenom SNP genotyping. Heat map analysis plots generated by R v2.15.1
visualize the number of matched SNP calls between paired samples. Positive (Pos1-T/N and Pos2-T/N) and negative (Neg1 and Neg2) controls are
included in each heat map. Match failures are considered to be in the range of 0–38 SNP matches, while matched samples (38–45 SNP matches) are
shown in pink.
doi:10.1371/journal.pone.0088163.g002
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demonstrated that decreasing amplicon size is most appropriate
for retrieving improved results overall.
Conclusions
Altogether, the data presented in this report support the efficacy
of Sequenom Bioscience’s Sample ID PlusH SNP assay technology
in generating genotype profiles from FFPE tissue DNA to achieve
accurate sample authentication for NGS application. The high
genotyping success rate of this assay provided more definitive
tumor/normal pair match results for FFPE samples than the
corresponding STR profiles. It has been observed that SNP
genotyping with this panel may not be adequate for forensic
analysis due to low DNA input requirements and a lack of
sensitivity [18]. However, this SNP genotyping platform is a
promising and suitable alternative to STR profiling for NGS
sample identification, especially for FFPE tissue DNA of lower
integrity. In the future, application of the Sample ID PlusH panel
as a quality control checkpoint before NGS library preparation
will add cost savings by reducing rework due to sample
mismatches. Furthermore, the ability to utilize FFPE-derived
retrospective DNA samples for genomic analyses will be extremely
important in cancers such as prostate cancer where the long
natural history of the disease limits prospective assessments.
Figure 3. SNP amplicon size does not indicate SNP call failure. All 45 SNPs are plotted according to size for intact R1 reference gDNA and
each R1 fragment pool. Failed SNP calls are represented by blue diamonds and successful SNP calls are shown as red squares. Amplicon sizes range
from 76–139 bp. One SNP amplicon of 128 bp (dbSNP ID rs733164) does not amplify in all instances. For R1 132, amplification fails for 14 additional
SNPs ranging in size from 97–139 bp.
doi:10.1371/journal.pone.0088163.g003
Table 1. STR marker amplification for R1 fragment pools and intact R1 DNA.
STR Marker Amplicon Size (nt) R1 132 R1 233 R1 347 R1 450 R1 C1 C2
D19S433 101–135 Y Y Y Y Y Y Y
D3S1358 111–140 Y Y Y Y Y Y Y
D8S1179 122–169 Y Y Y Y Y Y Y
D5S818 134–172 Y Y Y Y Y Y Y
TH01 163–202 Y Y Y Y Y Y Y
vWA 154–206 Y Y Y Y Y Y Y
D21S11 184–240 Y Y Y Y Y Y Y
D13S317 216–244 N Y Y Y Y Y Y
TPOX 222–250 Y Y Y Y Y Y Y
D7S820 255–292 N N Y Y Y Y Y
D16S539 252–292 N N Y Y Y Y Y
CSF1PO 304–341 N N N Y Y Y Y
D18S51 262–344 N N Y Y Y Y Y
FGA 214–355 Y Y Y Y Y Y Y
D2S1338 306–359 N N Y Y Y Y Y
doi:10.1371/journal.pone.0088163.t001
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Supporting Information
Figure S1 Multiplex PCR amplification of target
GAPDH regions. Tumor samples (T1-2, T2-2, T3S1-2, T3S2-
2, and T4-2) display failed or lower amplification of larger targets.
Corresponding normal samples (N1-2, N2-2, N3-2, N4-2) are
shown for comparison. A no template control (NTC) and a
positive reference control (R1 (Pos)) lane are shown.
(TIF)
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